Bladder tumor markers: Need, nature and application. 1 Nucleus-based markers

International Urogynecology Journal

Volumn 9, Issue 4, 1998, Pages 221-227

  Kirollos, M M ^a,b   McDermott, S ^a,b   Bradbrook, R A ^a  

^a TORBAY HOSPITAL   (United Kingdom)

^b NONE   (United Kingdom)

Author keywords

Bladder tumor antigens markers; Cytology; Cytometry; Ki67; NMP22; P53; Telomerase

Indexed keywords

MONOCLONAL ANTIBODY KI 67; PROTEIN P53; TELOMERASE; TUMOR MARKER;

BLADDER TUMOR; CANCER INVASION; CLINICAL TRIAL; CYTOLOGY; CYTOMETRY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; META ANALYSIS; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SUPERFICIAL CANCER; URINE; UROGENITAL TRACT TUMOR;

EID: 0031711339     PISSN: 09373462     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01901608     Document Type: Review

References (68)

1. Cancer Research Campaign. Incidence-UK, Factsheet 1.1, 1994
2. American Cancer Society. Cancer Facts and Figures, Leading sites of new cancer cases and deaths. 1996 estimates. 1996, p. 11.
3. Abel PD. Follow-up of patients with "superficial" transitional cell carcinoma of the bladder: the case for a change in policy. Br J Urol 1993;72:135-142
4. Fradet Y. Cordon-Cardo C. Critical appraisal of tumor markers in bladder cancer. Semin Urol 1993;11:145-153
5. Jordan AM, Weingarten J, Murphy WM. Transitional cell neoplasms of the urinary bladder. Can biologic potential be predicted from histologic grading? Cancer 1987;60:2766-2774
6. Kiemeney LALM, Witjes JA, Heijbroek RP, Verbeek ALM, Debruyne FMJ. Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. J Urol 1993;150:60-64
7. Parmar MKB, Freedman LS, Hargreave TB, Tolley DA. Prognostic factors for recurrence and follow-up policies in the treatment of superficial bladder cancer: report from the British Medical Research Council subgroup on superficial bladder cancer (urological cancer working party). J Urol 1989;142:284-288
8. Woolhandler S, Pels RJ, Bor DH, Himmelstein DU, Lawrence RS. Dipstick urinalysis screening of asymptomatic adults for urinary tract disorders. 1 - Hematuria and proteinuria. JAMA 1989;262:1215-1219
9. Sarosdy MF. Data interpretation and integration of new tests into clinical practice (Editorial). J Urol 1997;158:2107-2108
10. Mao L, Schoenberg MP, Scicchitano M et al. Molecular detection of primary bladder cancer by analysis. Science 1995;271:659-662
11. Schwalb DM, Herr HW, Fair WR. The management of clinically unconfirmed positive urinary cytology. J Urol 1993;150:1751-1756
12. Golijanin D, Sherman Y, Shapiro A, Pode D. Detection of bladder tumors by immunostaining of the Lewis X antigen in cells from voided urine. Urology 1995;46:173-177
13. Klein FA, White FKH. Flow cytmetry deoxyribonucleic acid determinations and cytology of bladder washings: practical experience. J Urol 1988;139:275-278
14. Parry WL, Hemstreet GP. Cancer detection by quantitative fluorescence image analysis. J Urol 1988;139:270-274
15. Walther PJ. "Wildcatting" for breakthroughs in urothelial cancer detection and management - a frustrating business. (Editorial). J Urol 1995;154:1348-1350
16. Murphy WM, Rivera-Ramirez I, Medina CA, Wright NJ, Wajsman Z. The bladder tumor antigen (BTA) test compared to voided urine cytology in the detection of bladder neoplasms. J Urol 1997;158:2102-2106
17. Fair WR, Heston WDW. Overview of cancer biology and principles of oncology. In: Walch PC, Retik AB, Stamey AT, Vaughan ED (eds) Campbell's urology; Philadelphia: W B Saunders, 1992;1031-1052
18. Badalament RA. More is simply more and not necessarily better (Editorial). J Urol 1996;156:61-62
19. DNA content and proliferation activity in superficial transitional cell carcinoma of the bladder. Anticancer Res 1997;17:781-786
20. Simak R, Weiener H, Foeger A et al. Cytophotometry in the monitoring of bladder cancer under intravesical chemotherapy. Eur Urol 1996;29:391-398
21. Shackney SE, Berg G, Simon SR et al. Origins and clinical implications of aneuploidy in early bladder cancer. Cytometry 1995;22:307-316
22. Raitanen MP, Tammela TL, Kallioinen M, Isola J. P53 accumulation, deoxyribonucleic acid ploidy and progressive bladder cancer. J Urol 1997;157:1250-1253
23. Lee SE, Park MS. Prognostic factors for survival in patients with transitional cell carcinoma of the bladder: evaluation by histopathologic grade, pathologic stage and flow-cytometric analysis. Eur Urol 1996;29:193-198
24. Al-Abadi H, Nagel R. Deoxyribonucleic acid content and survival rates of patients with transitional cell carcinoma of the bladder. J Urol 1994;151:37-42
25. Bittard H, Lamy B, Billery C. Clinical evaluation of cell deoxyribonucleic acid content measured by flow cytometry in bladder cancer. J Urol 1996;155:1887-1891
26. Tetu B, Allard P, Fradet Y, Roberge N, Bernard P. Prognostic significance of nuclear DNA content and S-phase fraction by flow cytometry in primary papillary superficial bladder cancer. Hum Pathol 1996;27:922-926
27. Miyakawa A, Tachibana M, Nakashima J, Deguchi N, Baba S, Tazaki H. Flow cytometric bromodeoxyuridine/deoxyribonucleic acid bivariate analysis for predicting tumor invasiveness of upper tract urothelial cancer. J Urol 1994;152:76-80
28. Tachibana M, Deguchi N, Baba S, Jitsukawa S, Hata M, Tazaki H. Prognostic significance of bromodeoxyuridine high labeled bladder cancer measured by flow cytometry: does flow cytometric determination predict the prognosis of patients with transitional cell carcinoma of the bladder. J Urol 1993;149:739-743
29. Lee SH, Lin JS, Tzai TS et al. Prognostic factors of primary transitional cell carcinoma of the upper urinary tract. Eur Urol 1996;29:266-270
30. Slaton JW, Dinney CP, Veltri RW et al. Deoxyribonucleic acid ploidy enhances the cytological prediction of recurrent transitional cell carcinoma of the bladder. J Urol 1997;158:806-811
31. Neulander E, Kaneti J, Chaimovitz C, Sion-Vardy N, Douvdenani A. Deoxyribonucleic acid ploidy and the clinical pattern of grade 2 superficial cancer. J Urol 1997;157:1254-1259
32. Tachibana M, Miyakawa K, Baba S, Merai M, Tazaki H. Role of proliferative activity estimated by bromodeoxyuridine labeling index in determining predictive factors of recurrence in superficial intermediately malignant bladder tumors. J Urol 1996;156:63-69
33. Catalona WJ. Urothelial tumors of the urinary tract. In: Walch PC, Retik AB, Stamey AT, Vaughan ED (eds) Campbell's urology: Philadelphia: WB Saunders, 1992:1094-1158
34. Scher HI. Neoadjuvant versus adjuvant chemotherapy in invasive bladder cancer. Recent Results Cancer Res 1993;126:189-205
35. Pinnock CB, Roxby DJ, Ross JM, Pozza CH, Marshall VR. Ploidy and Tn-antigen expression in the detection of transitional cell neoplasia in non-tumour-bearing patients. Br J Urol 1995;75:461-469
36. Nakopoulou L, Constantinides C, Papandropoulos J et al. Evaluation of overexpression of P53 tumor suppressor protein in superficial and invasive transitional cell bladder cancer: comparison with DNA ploidy. Urology 1995;46:334-340
37. Pycha A, Mian C, Haitel A, Hofbauer J, Wiener H, Marberger M. Fluorescence in situ hybridization identifies more aggressive types of primarily noninvasive (stage pTa) bladder cancer. J Urol 1997;157:2116-2119
38. Chern H, Becich MJ, Persad RA et al. Clonal analysis of human recurrent superficial bladder cancer by immunohistochemistry of P53 and retinoblastoma proteins. J Urol 1996;156:1846-1849
39. Cordon-Cardo C, Sheinfeld J, Dalbagni G. Genetic studies and molecular markers of bladder cancer. Semin Surg Oncol 1997;13:319-327
40. Cordon-Cardo C, Reuter VE. Alterations of tumor suppressor genes in bladder cancer. Semin Diagn Pathol 1997;14:123-132
41. Cerutti P, Hussain P, Pourzand F. Mutagenesis of th H-ras protooncogene, and the p53 tumor suppressor gene. Cancer Res 1994;54:1934-1938
42. Mao L. Genetic alterations as clonal markers for bladder cancer detection in urine. J Cell Biochem 1996;25:191-196
43. Tsuji M, Kojima K, Murakami Y, Kanayama H, Kagawa S. Prognostic value of Ki-67 antigen and p53 protein in urinary bladder cancer: immunohistochemical analysis of radical cystectomy specimens. Br J Urol 1997;79:367-372
44. Esrig D, Elmajian D, Groshen S et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 1994;331:1259-1264
45. Serth J, Kuczyk MA, Bokemeyer C et al. P53 immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder. Br J Cancer 1995;71:201-105
46. Kuczyk MA, Bokemeyer C, Serth J et al. P53 overexpression as a prognostic factor for advanced stage bladder cancer. Eur J Cancer 1995;31A:2243-2247
47. Griffiths TR, Mellon JK, Pyle GA, Shenton BK, Neal DE. P53 and ploidy assessed by flow cytometry in bladder washings. Br J Urol 1995;76:575-579
48. Thomas DJ, Robinson MC, Charlton R, Wilkinson S, Shenton BK, Neal DE. P53 expression, ploidy and progression in pT1 transitional cell carcinoma of the bladder. Br J Urol 1994;73:533-537
49. Terrell EB, Cheville JC, See WA, Cohen MB. Histopathological features and p53 nuclear protein staining as predictors of survival and tumor recurrence in patients with transitional cell carcinoma of the renal pelvis. J Urol 1995;154:1342-1347
50. Vet JA, Debruyne FM, Schalken JA. Molecular prognostic factors in bladder cancer. World J Urol 1994;12:84-88
51. Hruban RH, Van Der Riet P, Erozan YS, Sidransky D. Brief report: molecular biology and the early detection of carcinoma of the bladder - the case of Hubert H. Humphrey. N Engl J Med 1994;330:1276-1278
52. Shiina H, Igawa M, Yagi H et al. Immunohistochemistry of p53 protein in transitional-cell carcinoma of the bladder using an image analyzer. Oncology 1996;53:233-240
53. Caliskan M, Turkeri LN, Mansuroglu B et al. Nuclear accumulation of mutant p53 protein: a possible predictor of failure of intravesical therapy in bladder cancer. Br J Urol 1997;79:373-377
54. Lebert T, Becette V, Barbagelatta M et al. Correlation between p53 over expression and response to Bacillus Calmette-Guérin therapy in high risk patients with T1G3 bladder cancer. J Urol 1998;159:788-791
55. Sarkis AS, Dalbagni G, Cordon-Cardo C et al. Association of p53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J Urol 1994;152:388-392
56. Ovesen H, Horn T, Steven K. Long-term efficacy of intravesical Bacillus Calmette-Guérin for carcinoma in situ: relationship of progression to histological response and p53 nuclear accumulation. J Urol 1997;157:1655-1659
57. Yoshida K, Sugino T, Tahara H et al. Telomerase activity in bladder carcinoma and its implication for noninvasive diagnosis by detection of exfoliated cancer cells in urine. Cancer 1997;79:362-369
58. Kamata S, Kageyama Y, Yonese J, Oshima H. Significant telomere reduction in human superficial transitional cell carcinoma. Br J Urol 1996;78:704-708
59. Kyo S, Kunimi K, Uchibayashi T, Namiki M, Inoue M. Telomerase activity in human urothelial tumors. Am J Clin Pathol 1997;107:555-560
60. Kageyama Y, Kamata S, Yonese J, Oshima H. Telomere length and telomerase activity in bladder and prostate cancer cell lines. Int J Urol 1997;4:407-410
61. Kinoshita H, Ogawa O, Kakehi Y et al. Detection of telomerase activity in exfoliated cells in urine from patients with bladder cancer. J Natl Cancer Inst 1997;89:724-730
62. Yang SC, Lee DH, Hong SJ, Chung BH, Kim IY. Telomerase activity: a potential marker of bladder transitional cell carcinoma in bladder washes. Yonesei Med J 1997;38:155-159
63. Carpinto GA, Stadler WM, Briggman JV et al. Urinary nuclear matrix protein as a marker for transitional cell carcinoma of the urinary tract. J Urol 1996;156:1280-1285
64. Miyanaga N, Akaza H, Ishikawa S et al. Clinical evaluation of nuclear matrix protein 22 (NMP22) in urine as a novel marker for urothelial cancer. Eur Urol 1997;31:163-168
65. Soloway MS, Briggman JV, Arpinito GA et al. Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurrent transitional cell carcinoma of the urinary tract following surgical treatment. J Urol 1996;156:363-367
66. Akaza H, Miyanaga N, Tsukamoto T et al. Evaluation of nuclear matrix protein 22 (NMP22) as a disgnostic marker for bladder cancer: a multicentre trail in Japan. J Urol 1997;157:337, Abstract 1315
67. Briggman JV, Merrifield SA, Halvorsen MJ et al. Measurement of a nuclear matrix protein in the urine of patients with bladder cancer. Proc Am Assoc Cancer Res 1994;35:15, Abstract 89
68. Asakura T, Takano Y, Iki M et al. Prognostic value of Ki-67 for recurrence and progression of superficial bladder cancer. J Urol 1997;158:385-388